[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100243319":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":33,"locations":39,"responsibleParty":67,"collaborators":70,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":32,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":32,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":32,"overallStatus":41,"whyStopped":32,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"University of Maryland, Baltimore","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"90 mg\u002Fdl glucose clamp","EXPERIMENTAL","Glucose clamp intervention of 90 mg\u002Fdl maintained for 90 minutes.",[13],"Device: Glucose clamp",{"label":15,"type":10,"description":16,"interventionNames":17},"70 mg\u002Fdl glucose clamp","Glucose clamp intervention of 70 mg\u002Fdl maintained for 90 minutes.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"60 mg\u002Fdl glucose clamp","Glucose clamp intervention of 60 mg\u002Fdl maintained for 90 minutes.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"50 mg\u002Fdl glucose clamp","Glucose clamp intervention of 50 mg\u002Fdl maintained for 90 minutes.",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DEVICE","Glucose clamp","Different levels of hypoglycemia",[23,19,15,9],null,[34],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"Maka Siamashvili, MD","CONTACT","410-706-5623","msiamashvili@som.umaryland.edu",[40,58],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Baltimore","Maryland","21201","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-76.61219,39.29038,{"lat":51,"lon":50},[54,55],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":32},{"name":56,"role":57,"phone":32,"phoneExt":32,"email":32},"Stephen N Davis, MBBS","PRINCIPAL_INVESTIGATOR",{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":59,"geoPoint":61,"contacts":62},{"type":48,"coordinates":60},[50,51],{"lat":51,"lon":50},[63,64,66],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":32},{"name":65,"role":36,"phone":37,"phoneExt":32,"email":38},"Maka Hedrington, MD",{"name":56,"role":57,"phone":32,"phoneExt":32,"email":32},{"type":57,"investigatorFullName":68,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"Stephen N. Davis, MBBS","Chairman of Medicine",[71],{"name":72,"class":6},"Vanderbilt University","100243319","early-phase-1-differing-levels-of-hypoglycemia-100243319",false,"NCT02445781","Differing Levels of Hypoglycemia","Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Differing Levels of Hypoglycemia","Inclusion Criteria:\n\n• Body mass index \\>21kg · m-2\n\nExclusion Criteria:\n\n* Pregnant women\n* Subjects unwilling or unable to comply with approved contraception measures\n* Subjects unable to give voluntary informed consent\n* Subjects on anticoagulant drugs, anemic or with known bleeding diatheses\n* Subjects with a history of severe, uncontrolled hypertension, heart disease, cerebrovascular incidents\n* Current tobacco use\n* Subjects with any known allergies to any of the study medications being used\n\nPhysical Exam Exclusion Criteria\n\n* Uncontrolled severe hypertension (i.e., blood pressure greater than 160\u002F100)\n* Clinically significant cardiac abnormalities (e.g. heart failure, arrhythmia)\n* Pneumonia treatment or hospitalization within 2 weeks prior to enrollment (study visit)\n* Hepatic failure \u002F jaundice\n* Renal failure\n* Cerebrovascular accident occurrence or hospitalization within 4 weeks prior to enrollment\n* Fever greater than 38.0 degrees C\n\nScreening Laboratory Tests Exclusion Criteria\n\n* Hematocrit lower than 32 %\n* White blood cell (WBC) count lower than 3 thou\u002Ful or greater than 14 thou\u002Ful\n* Liver function tests: serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic-pyruvic transaminase (SGPT) greater than twice upper limit of normal range\n* Alkaline phosphatase greater than 150U\u002FL\n* Total bilirubin (TBil) greater than 2 mg\u002Fdl\n* Estimated glomerular filtration rate (eGFR) less than 60 mL\u002Fmin\u002F1.73 m2\n* Positive human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C\n* Any abnormal cardiac response during multi-stage exercise test (if over 40 years of age)",true,"ALL","18 Years","55 Years",{"count":85,"type":86},32,"ESTIMATED","INTERVENTIONAL",[89],"EARLY_PHASE1","Hypoglycemia can produce a spectrum of pro-inflammatory and pro-atherothrombotic changes. To date no studies appear to have investigated the effects of differing levels of hypoglycemia on the vasculature and pro-atherothrombotic balance during hypoglycemia in healthy man. The specific aim of our study will be to determine the effects of differing levels of hypoglycemia on in-vivo vascular biologic mechanisms in a healthy population.",[92],"Hypoglycemia","2025-11-05",{"date":95,"type":96},"2025-11-10","ACTUAL",{"date":98,"type":32},"2015-07",{"date":100,"type":86},"2026-12",{"name":5,"class":6},2]